Figure 6.
Serum concentrations of serum amyloid P (SAP) are associated with disease activity in the oxazolone-induced colitis model. Female SJL mice were sensitized and challenged with oxazolone. Starting the day before intrarectal challenge (Day −1), mice were administered bifunctional interleukin-4 (IL-4) /IL-13 antagonist, at 8, 3, or 0·5 mpk every 2 days. At time of killing on Day 7, sera were collected and assayed for SAP by ELISA. Associations between these readouts and disease correlates are shown for all animals in the study, across all treatment groups: (a) average body weight versus serum SAP; (b) colon length versus serum SAP; (c) serum bifunctional IL-4/IL-13 antagonist concentration versus colon length; (d) serum concentrations of bifunctional IL-4/IL-13 antagonist versus SAP for the 0·5 mpk dose group. R2 and P-values were derived from linear regression analysis.